Table 1 Ferroptosis-inducing agents and mechanisms of action
From: Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma
Compound Name | Mechanism of Action | Reference |
|---|---|---|
Altretamine | GPX4 inhibitor | |
Artesunate | Iron-dependent ROS production via dihydroartemisin formation, downregulation of GPX4 and inhibition of glutathione S-transferase (GST) | |
Auranofin | Thioredoxin Reductase (TRXR) inhibitor | |
Buthionine Sulfoximine (BSO) | Inhibition of GSH synthesis | |
Cisplatin | Depletion of GSH, model dependent | |
Docosahexaenoic acid (DHA) | n-3 PUFA supplementation, enhanced lipid peroxidation | |
Erastin | System Xc- inhibitor | |
FIN56 | Degradation of GPX4 and depletion of coQ10 | |
Fluvastatin | HMG-CoA reductase inhibitor | |
Ironomycin | Upregulation of Tf receptor and iron-mediated peroxidation of lysosomal membranes | |
Lovastatin | HMG-CoA reductase inhibitor | |
ML162 | GPX4 inhibitor | |
ML210 | GPX4 inhibitor | |
(1S,3 R)-Ras Selective Lethal 3 (RSL3) | GPX4 inhibitor | |
Salinomycin | Upregulation of Tf receptor and iron-mediated peroxidation of lysosomal membranes | |
Sulfasalazine (SAS) | System Xc- inhibitor | |
Sorafenib | System Xc- inhibitor |
